Stryker Corporation (SYK)
Stryker: Wait For A Better Entry Point Post-Q2 Results
Stryker is a global medical products and devices company that has global operations in over 75 countries. Historically, the company has been a compounder, generating high returns on capital and has put up impressive top and bottom line growth rates. Recent second quarter results showed strong growth in orthopedics and international markets, with a beat on both revenue and EPS.
Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
Are Medical Stocks Lagging Stryker (SYK) This Year?
Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.
Stryker Corporation (SYK) Q2 2024 Earnings Call Transcript
Stryker Corporation (NYSE:SYK ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JP Morgan Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Shagun Singh Chadha - RBC Matthew Miksic - Barclays Steve Lichtman - Oppenheimer Vijay Kumar - Evercore ISI Matthew Taylor - Jefferies Joshua Jennings - TD Cowen Danielle Antalffy - UBS Michael Matson - Needham Caitlin Cronin - Canaccord Jayson Bedford - Raymond James Andrew Ranieri - Morgan Stanley David Roman - Goldman Sachs Operator Welcome to the Second Quarter 2024 Stryker Earnings Call. My name is Luke, and I'm your operator for today's call.
Stryker beats Q2 profit estimates on robust demand for medical devices, implants
Stryker Corp posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries.
Stryker (SYK) Tops Q2 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.54 per share a year ago.
Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Stryker (SYK) Completes Artelon's Acquisition to Boost Business
Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.
Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System
Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.
